Financial Performance - The company reported a significant increase in revenue for the first half of 2023, with total revenue reaching RMB 150 million, representing a 25% year-over-year growth[11]. - The company's operating revenue for the first half of 2023 was approximately CNY 135.13 million, representing a year-on-year increase of 17.10% compared to CNY 115.39 million in the same period last year[17]. - The net profit attributable to shareholders was CNY 39.18 million, a slight increase of 0.10% from CNY 39.14 million in the previous year[17]. - The gross margin for the first half of 2023 improved to 60%, up from 55% in the previous year, reflecting better cost management and pricing strategies[11]. - The company achieved a total revenue of 6,100 million RMB, with a net profit of 309.94 million RMB, reflecting a significant increase in performance compared to the previous year[49]. - The net profit for the first half of 2023 was CNY 54,999,328.37, compared to CNY 51,067,347.09 in the first half of 2022, reflecting a growth of about 7.4%[192]. Market Expansion and Product Development - The company has provided a positive outlook for the second half of 2023, projecting a revenue growth of 20% to 30% based on current market trends and product demand[11]. - New product development is underway, with three innovative medical devices expected to launch by Q4 2023, aimed at enhancing surgical efficiency and patient outcomes[11]. - The company is expanding its market presence, targeting an increase in distribution channels by 40% in the next year, particularly in tier-2 and tier-3 cities[11]. - The company aims to enhance its product lines in neurosurgery, oral surgery, and cardiothoracic surgery, focusing on market-driven and industrialization goals[28]. - The company is focusing on expanding its market presence through product innovation and process improvement, with a strategic plan to integrate dental implant systems and digital surgical tools[53]. Research and Development - The company has invested RMB 20 million in R&D for new technologies, focusing on biocompatible materials and advanced surgical instruments[11]. - Research and development expenses accounted for 6.12% of operating revenue, an increase of 0.91 percentage points from the previous year[18]. - The total R&D expenditure for the reporting period was ¥8,275,666.55, representing a 37.73% increase compared to ¥6,008,783.71 in the same period last year[44]. - The company has obtained a total of 13 invention patents as of the end of the reporting period, with 1 new application filed during this period[42]. - The company is focused on developing a 3D printing method for personalized PEEK cranial implants, which aims to overcome challenges in traditional mechanical processing methods[47]. Financial Position and Cash Flow - The company has maintained a strong cash position, with cash and cash equivalents totaling RMB 100 million as of June 30, 2023[11]. - The net cash flow from operating activities decreased by 30.56% to CNY 32.38 million, primarily due to the payment of deferred taxes from the previous year[19]. - Cash and cash equivalents decreased by 44.32% to ¥194,453,926.40, primarily due to the purchase of structured deposits[74]. - The company's total assets for the reporting period were significantly impacted by the changes in cash and investments[74]. - The ending cash and cash equivalents balance was RMB 194,453,926.40, a decrease from RMB 211,560,715.95 at the end of the first half of 2022[195]. Risks and Challenges - No significant risks were identified that could materially impact the company's operations during the reporting period[11]. - The company faces risks related to new product development failures and market demand changes, which could adversely affect its long-term competitiveness[65]. Regulatory and Compliance - The company has established a comprehensive quality management system, ensuring compliance with domestic quality standards and obtaining FDA and CE certifications for multiple products[56]. - The company has committed to avoiding and reducing any form of related party transactions[140]. - The company will ensure timely and truthful reporting of any changes in shareholding by its directors and senior management[103]. Shareholder Information - Major shareholders are prohibited from transferring or managing their shares during the lock-up period[96]. - The company has a commitment to not reduce shares below the initial public offering price during the lock-up period[96]. - Shareholders holding over 5% of shares express confidence in the company's business prospects and plan to hold shares long-term post-lock-up[116].

证券代码：688314 证券简称：康拓医疗 公告编号：2023-024 西安康拓医疗技术股份有限公司 2023年半年度募集资金存放与实际使用情况 的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、 募集资金基本情况 （一）实际募集资金金额和资金到账时间 经中国证券监督管理委员会出具的《关于同意西安康拓医疗技术股份有限公 司首次公开发行股票注册的批复》（证监许可[2021]959 号）核准，并经上海证券 交易所同意，公司首次公开发行人民币普通股（A 股）1,451.00 万股。募集资金 总额为人民币251,603,400.00元，扣除不含税的发行费用人民币43,355,571.58元， 募集资金净额为人民币 208,247,828.42 元。本次募集资金已于 2021 年 5 月 13 日 全部到位，中审众环会计师事务所（特殊普通合伙）于 2021 年 5 月 13 日对资金 到位情况进行了审验，并出具了《验资报告》（众环验字[2021] 0800005 号）。 公司已按照相关规定对募集资金采取了专户存储管理， ...

西安康拓医疗技术股份有限公司 独立董事关于第二届董事会第六次会议相关事项的 独立意见 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《上海证券交易所 科创板上市规则》、《西安康拓医疗技术股份有限公司章程》（以下简称"《公司章 程》"）等有关规定，我们作为西安康拓医疗技术股份有限公司（以下简称"公司"） 的独立董事，认真审阅了第二届董事会第六次会议相关的会议资料和文件，基于 独立客观的立场，本着实事求是的原则，对本次会议审议的有关事项发表独立意 见如下： 一、关于募集资金存放与实际使用情况的专项报告的独立意见 经核查，我们认为：公司 2023 年半年度募集资金存放与实际使用情况符合 《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要求》、《上 海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》及公司《募集 资金使用管理办法》等法律法规的规定，对募集资金进行了专户存储和专项使用， 并及时履行了相关信息披露义务，募集资金具体使用情况与公司已披露情况一致， 不存在变相改变募集资金用途和损害股东利益的情况，不存在违规使用募集资金 的情形。我们一致同意公司董事会出具的 2023 年半 ...

证券代码：688314 证券简称：康拓医疗 公告编号：2023-025 西安康拓医疗技术股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2023 年 08 月 24 日(星期四)下午 15:00-16:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 08 月 17 日(星期四)至 08 月 23 日(星期三)16:00 前登 录上证路演中心网站首页点击 " 提问预征集 " 栏目或通过公司邮箱 public@kontmed.com 进行提问。公司将在说明会上对投资者普遍关注的问题进 行回答。 西安康拓医疗技术股份有限公司（以下简称"公司"）已于 2023 年 8 月 16 日发布公司 2023 年半年度报告，为便于广大投资者更全面深入地了解公司 2023 年半年度经 ...

证券代码：688314 证券简称：康拓医疗 公告编号：2023-023 西安康拓医疗技术股份有限公司 第二届监事会第五次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 西安康拓医疗技术股份有限公司(以下简称"公司")第二届监事会第五次会 议于 2023 年 8 月 14 日在公司会议室以现场的方式召开，会议通知已于 2023 年 8 月 3 日通过邮件的方式送达全体监事。本次会议由监事会主席帖凯先生主持， 会议应出席监事 3 人，实际出席监事 3 人。会议召开符合《中华人民共和国公司 法》《上海证券交易所科创板股票上市规则》等有关法律、行政法规、部门规章、 规范性文件和《西安康拓医疗技术股份有限公司章程》的规定，会议召开合法、 有效。 二、监事会会议审议情况 经与会监事审议表决，形成会议决议如下: （一）审议通过《关于公司 2023 年半年度报告及摘要的议案》 表决结果：同意票 3 票，反对票 0 票，弃权票 0 票。 经审核，监事会认为：公司 2023 年半年度报告及其摘要的编制和审 ...

证券代码：688314 证券简称：康拓医疗 公告编号：2023-024 西安康拓医疗技术股份有限公司 2023年半年度募集资金存放与实际使用情况 的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、 募集资金基本情况 （一）实际募集资金金额和资金到账时间 经中国证券监督管理委员会出具的《关于同意西安康拓医疗技术股份有限公 司首次公开发行股票注册的批复》（证监许可[2021]959 号）核准，并经上海证券 交易所同意，公司首次公开发行人民币普通股（A 股）1,451.00 万股。募集资金 总额为人民币251,603,400.00元，扣除不含税的发行费用人民币43,355,571.58元， 募集资金净额为人民币 208,247,828.42 元。本次募集资金已于 2021 年 5 月 13 日 全部到位，中审众环会计师事务所（特殊普通合伙）于 2021 年 5 月 13 日对资金 到位情况进行了审验，并出具了《验资报告》（众环验字[2021] 0800005 号）。 公司已按照相关规定对募集资金采取了专户存储管理， ...

证券代码：688314 证券简称：康拓医疗 公告编号：2023-018 西安康拓医疗技术股份有限公司 为充分尊重投资者、提升交流的针对性，投资者可于 2023 年 5 月 14 日 17:00 前通过公司邮箱 public@kontmed.com 进行提问。公司将在说明会上对投资者普 遍关注的问题进行回答。欢迎广大投资者积极参与本次网上说明会。 特此公告。 西安康拓医疗技术股份有限公司董事会 2023 年 5 月 9 日 西安康拓医疗技术股份有限公司（以下简称"公司"）已于 2023 年 3 月 24 日发布公司 2022 年年度报告，为促进公司规范运作、健康发展，增强公司信息 透明度，加强与广大投资者沟通交流，进一步提升投资者关系管理水平，公司将 于 2023 年 5 月 16 日参与"2023 年陕西辖区上市公司投资者集体接待日暨 2022 年度业绩说明会活动"。 届时，公司董事长胡立人先生，董事会秘书周欢先生，财务总监沈亮先生（如 有特殊情况，参会人员将可能进行调整）将通过互动平台与投资者进行网络沟通 和交流，欢迎广大投资者踊跃参加。 活动时间：2023 年 5 月 16 日 15:00-17:00。 ...

Financial Performance - The company achieved operating revenue of CNY 239.95 million in 2022, an increase of 12.89% compared to 2021[20]. - Net profit attributable to shareholders was CNY 75.70 million, a decrease of 7.26% from the previous year[20]. - The net profit after deducting non-recurring gains and losses was CNY 67.98 million, an increase of 2.38% year-on-year[20]. - The company's cash flow from operating activities was CNY 91.98 million, down 10.95% from 2021[18]. - The total assets at the end of 2022 were CNY 638.14 million, an increase of 11.29% compared to the end of 2021[18]. - Basic earnings per share decreased to CNY 1.30, down 17.20% from 2021[19]. - The weighted average return on equity decreased to 14.64%, down 6.2 percentage points from 2021[19]. - The company reported a net profit margin of 722.32% for the year[136]. - The company's total revenue for the year reached approximately 22,011.93 million RMB, representing a 53.07% increase compared to the previous year[95]. Dividend and Share Capital - The company plans to distribute a cash dividend of 5.20 RMB per 10 shares, totaling approximately 30.17 million RMB, which represents 39.86% of the net profit attributable to shareholders for 2022[4]. - The company will increase its total share capital from 58,027,980 shares to 81,239,172 shares after a capital reserve conversion of 4 shares for every 10 shares held[4]. - The total cash dividend amount accounted for 39.86% of the net profit attributable to ordinary shareholders in the consolidated financial statements[162]. - The company has implemented a cash dividend policy that is compliant with its articles of association and shareholder resolutions[159]. Research and Development - The company’s R&D investment accounted for 7.63% of operating revenue, a decrease of 0.28 percentage points from the previous year[19]. - The total R&D investment for the year was ¥18,301,085.39, an increase of 8.90% compared to the previous year[66]. - The cumulative number of patents held by the company reached 45, including 13 invention patents and 22 utility model patents[64]. - The company has obtained 6 new invention patents and 8 utility model patents during the reporting period, totaling 14 new patents[64]. - The company is developing a 3D printing technology using SLS for personalized processing of PEEK powder, aimed at producing skull repair plates[68]. - The company is also working on an antibacterial coating for drainage catheters, with an investment of ¥1,500,000[69]. - The company has initiated multiple R&D projects, including maxillofacial repair and antibacterial coating drainage tubes, aimed at expanding its product line in niche markets[75]. Market Expansion and Product Development - The company plans to continue promoting PEEK bone plates in the U.S. and increase investment in dental and thoracic surgery products[20]. - The company has gained market access in nearly 30 countries or regions overseas, with ongoing expansion efforts[39]. - The company is focusing on optimizing its product structure and enhancing its product pipeline to strengthen its market position in the neurosurgery field[33]. - The company aims to enhance its market share in the neurosurgery sector while expanding into overseas markets, particularly in the fields of thoracic and oral surgery[124]. - The company plans to respond to regional bulk procurement policies in neurosurgery to increase sales volume and market share[126]. - The company is exploring potential mergers and acquisitions to strengthen its market position[136]. Governance and Compliance - The company has a standard unqualified audit report from Zhongzheng Zhonghuan Accounting Firm[4]. - The company has no special arrangements for corporate governance[6]. - The company has established a comprehensive internal control system, which includes 103 revised clauses across nine governance-related regulations[164]. - The company has maintained a stable shareholding structure, with no significant changes reported during the period[132]. - The company has a structured approach to remuneration, referencing industry standards and individual responsibilities[143]. - The company has appointed independent directors to ensure compliance and strategic guidance in its operations[142]. Operational Efficiency and Cost Management - The company has transitioned the production of BIOPLATE titanium products to domestic facilities, enhancing operational efficiency and reducing costs[41]. - The company has implemented lean production practices to reduce waste and improve efficiency, contributing to carbon reduction efforts[177]. - The company has a robust quality management system, ensuring compliance with domestic quality standards and obtaining FDA and CE certifications for multiple products, which guarantees high quality and stability[77]. - The company has established a supplier evaluation system to ensure fair contracts and protect supplier rights[182]. Employee and Talent Management - The company has increased its workforce by 25.73%, with a 30.12% rise in sales and R&D personnel, improving its talent structure[40]. - The company plans to establish an online training platform for all employees to enhance soft skills and meet career development needs[157]. - The company aims to deepen training for key positions and improve project management skills to optimize talent development[157]. - The employee composition includes 101 production personnel, 58 sales personnel, 50 technical personnel, 11 financial personnel, and 39 administrative personnel[154]. Environmental Responsibility - The company invested 57,800 RMB in environmental protection during the reporting period[168]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[170]. - The company has implemented a waste management system for solid waste, with a total of 40m² for general waste storage and 10m² for hazardous waste storage[174]. - The company emphasizes environmental protection by ensuring that all waste management practices meet relevant standards[176]. Risks and Challenges - The company faces risks related to new product development and registration failures, which could adversely affect its long-term core competitiveness[80]. - The company is exposed to risks from rapid technological iterations and changing market demands, which could impact the application prospects of its ongoing projects[80]. - The company has a high dependency on its neurosurgical cranial repair fixation products, which accounted for 94.87% of its main business revenue in 2022, posing a risk if market conditions change[83]. - The company is facing challenges in the neurosurgery market due to low industry ceilings and cross-industry competition, prompting a strategy to acquire leading technologies and products through mergers and acquisitions[128].

Financial Performance - The company's operating revenue for Q1 2023 was ¥64,642,702.97, representing a year-on-year increase of 20.82%[5] - The net profit attributable to shareholders for the same period was ¥19,419,917.13, reflecting a growth of 7.70% compared to the previous year[5] - The basic earnings per share for Q1 2023 was ¥0.33, showing an increase of 6.45% from the same period last year[6] - The net profit for Q1 2023 was CNY 19,079,127.44, representing an increase of 8.5% compared to CNY 17,578,386.38 in Q1 2022[18] - Total revenue from operating activities reached CNY 78,281,483.00, up from CNY 58,527,987.95 in the same period last year, indicating a growth of 33.7%[21] - The total comprehensive income for the period was CNY 18,884,533.92, compared to CNY 17,491,604.14 in the same quarter last year, showing an increase of 8.0%[19] Research and Development - Research and development expenses totaled ¥4,000,571.62, which is an increase of 61.23% year-on-year, indicating a significant investment in innovation[6] - Research and development expenses increased to CNY 4,000,571.62, compared to CNY 2,481,241.25 in the previous year, reflecting a growth of 61.4%[18] Cash Flow and Assets - The net cash flow from operating activities was ¥13,837,410.61, which represents a decline of 11.62% year-on-year[5] - Cash and cash equivalents decreased to RMB 255,710,751.50 as of March 31, 2023, down from RMB 349,241,669.41 at the end of 2022, a decline of 26.7%[14] - The company reported a net cash flow from operating activities of CNY 13,837,410.61, a decrease from CNY 15,656,175.96 in Q1 2022[22] - The company incurred a net cash outflow from investing activities of CNY -108,821,161.64, an improvement from CNY -170,936,303.22 in the previous year[22] Assets and Liabilities - Total assets at the end of the reporting period were ¥645,679,581.22, an increase of 1.18% from the end of the previous year[6] - The total assets as of March 31, 2023, were RMB 645,679,581.22, compared to RMB 638,135,743.88 at the end of 2022, showing a slight increase of 1.1%[16] - The total liabilities decreased to RMB 85,113,166.39 as of March 31, 2023, from RMB 96,462,236.78 at the end of 2022, a reduction of 11.4%[16] - The equity attributable to shareholders increased to RMB 562,507,080.16 as of March 31, 2023, compared to RMB 543,283,167.02 at the end of 2022, an increase of 3.5%[16] Shareholder Information - The company had a total of 3,366 common shareholders at the end of the reporting period[10] - The largest shareholder, Hu Liren, holds 48.54% of the shares, amounting to 28,168,420 shares[10] Operational Efficiency - The total operating costs for Q1 2023 amounted to RMB 41,550,307.81, up from RMB 31,854,707.27 in Q1 2022, reflecting a growth of 30.5%[17] - The company reported a net profit margin improvement due to increased revenue and controlled costs, although specific profit figures were not disclosed in the provided content[17] - Sales and service cash receipts totaled CNY 75,942,249.47, up from CNY 57,473,707.41 in Q1 2022, marking a growth of 32.3%[20] Strategic Focus - The company is focusing on expanding its market presence and enhancing product development, although specific new products or technologies were not detailed in the provided content[17] - The company continues to focus on enhancing its financial position through strategic asset management and investment in growth opportunities[24]

Dividend and Profit Distribution - The company plans to distribute a cash dividend of 5.20 RMB per 10 shares (including tax) and to increase capital by 4 shares for every 10 shares held, resulting in a total cash dividend of 30,174,549.60 RMB and a capital increase of 23,211,192 shares[4]. - The cash dividend represents 39.86% of the net profit attributable to shareholders for the year 2022[4]. - The company distributed a cash dividend of 0.62 CNY per share, totaling 35,977,347.60 CNY for the reporting period[158]. - The cash dividend amount accounted for 39.86% of the net profit attributable to ordinary shareholders in the consolidated financial statements[162]. - The company revised its profit distribution policy to include specific conditions and decision-making procedures for cash dividends, ensuring protection for minority investors[158]. Financial Performance - The company achieved operating revenue of CNY 239,948,744.59 in 2022, representing a year-on-year increase of 12.89%[18]. - The net profit attributable to shareholders was CNY 75,698,150.91, a decrease of 7.26% compared to the previous year[20]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 67,982,008.71, an increase of 2.38% year-on-year[18]. - The company's cash flow from operating activities was CNY 91,975,607.52, down 10.95% from the previous year[18]. - The basic earnings per share decreased by 17.20% to CNY 1.30 in 2022[19]. - The company's total assets increased by 11.29% to CNY 638,135,743.88 at the end of 2022[18]. - The company achieved a gross margin of 81.94% in the medical device sector, with a revenue increase of 11.29% compared to the previous year[89]. - The company's total revenue for the year reached approximately 22,011.93 million, representing a 53.07% increase compared to the previous year[95]. - The company reported a gross margin of 45%, an improvement from 42% in the previous year[139]. Research and Development - The total R&D investment for the year was ¥18,301,085.39, an increase of 8.90% compared to the previous year[66]. - R&D investment as a percentage of operating revenue decreased to 7.63%, down by 0.28 percentage points from the previous year[66]. - The company has developed a full product line for cranial repair and fixation surgeries, including PEEK plates and titanium mesh, addressing diverse clinical needs[75]. - The company is actively pursuing multiple R&D projects, including maxillofacial repair and antibacterial coating drainage catheters, to expand its product offerings[75]. - The company has obtained 6 new invention patents and 8 utility model patents during the reporting period, totaling 14 new patents[64]. - The cumulative number of patents held by the company has reached 45, including 13 invention patents and 22 utility model patents[64]. - The company is developing a 3D printing technology using SLS for personalized processing of PEEK powder, aimed at producing skull repair plates[68]. - The company has improved its core technology for PEEK material, achieving better strength and flexibility in cranial fixation products[62]. Market Expansion and Product Development - The company plans to continue promoting PEEK bone plates in the U.S. and increase investment in dental and thoracic surgery products[20]. - The company is committed to expanding its oral business, which has formed a clear development plan and is expected to grow gradually[32]. - The company is expanding its international presence, with products sold in the US, EU, Brazil, Russia, Australia, and Southeast Asia, contributing to market expansion[77]. - The company plans to continue expanding its product promotion efforts and sales channels to enhance market penetration[86]. - The company is focusing on new product development and technology research to enhance market competitiveness[136]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 100 million allocated for potential deals[139]. Corporate Governance and Compliance - The company has received a standard unqualified audit report from Zhongzheng Zhonghuan Accounting Firm[4]. - There are no special arrangements for corporate governance or other significant matters applicable to the company[6]. - The company has not violated any regulatory decision-making procedures in providing guarantees[6]. - The company has established a comprehensive internal control system, which includes 103 revised clauses across nine governance-related regulations[164]. - The company has maintained a stable shareholding structure, with no significant changes reported among major shareholders during the reporting period[135]. - The company has a diverse management team with extensive experience in the medical technology sector[136]. Risks and Challenges - The company has not reported any significant risks that could materially affect its operations during the reporting period[3]. - The company faces risks related to new product development and registration failures, which could adversely affect long-term core competitiveness if projects fail[80]. - The company is exposed to risks from rapid technological iteration and changing market demands, which could impact the application prospects of ongoing projects[80]. - The company has a high dependency on its main product, with 94.87% of revenue coming from cranial repair fixation products in 2022, making it vulnerable to market changes[83]. Employee and Talent Management - The company has increased its workforce by 53 employees, a 25.73% increase year-on-year, with a 30.12% increase in sales and R&D personnel[40]. - The number of R&D personnel increased to 50, representing 19.31% of the total workforce, compared to 41 personnel and 20% in the previous period[74]. - The company plans to establish an online training platform for all employees to enhance soft skills training and meet career advancement needs[128]. - The company aims to optimize its talent management system, including job matrix and compensation assessment, to create a fair and transparent evaluation system[128]. Environmental Responsibility - The company invested 57,800 CNY in environmental protection during the reporting period[168]. - The company did not face any administrative penalties related to environmental issues during the reporting period[170]. - The company has implemented a lean production approach to reduce carbon emissions and improve efficiency, focusing on waste elimination and optimizing processes[177]. - The company has a dedicated emergency response plan for environmental incidents, enhancing its capability to manage public crises related to environmental pollution[175]. Investor Relations - The company held a total of 4 earnings briefings during the reporting period, including 1 online event and 3 specific audience research sessions[186]. - The company received over 100 investor relations emails and answered 117 investor calls, achieving a 100% response rate to 25 inquiries through the Shanghai Stock Exchange's "e-Interaction" platform[186]. - The company maintains a transparent information disclosure process, ensuring timely and accurate communication of significant information to investors[188]. - The company has committed to various share lock-up agreements for its major shareholders, ensuring compliance with regulations[193].